Study S001501

A Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

ClinicalTrials.gov record

Registration

Registration: NCT06965413
Acronym: GYMINDA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 285
Start: 2025-05-05
Primary completion: 2026-09-03
Lead sponsor: Hoffmann-La Roche
Conditions: Obesity; Overweight; Overweight With One Weight Related Comorbidity
Interventions: DRUG:RO7204239; DRUG:RO7204239 Matching Placebo; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2024-519561-22-00

Registered primary outcomes

Percent Change From Baseline in Body Weight [Baseline, Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.